Book Value per Share: Aprea Therapeutics (APRE)

Public company logo of Aprea Therapeutics (APRE)

How can suppressor proteins be restored in oncology? Accounting data regarding the share price of Aprea Therapeutics (APRE) demonstrates capital dynamics, where the current status equals 3.09. Business protection is ensured by patents for Eprenetapopt and influence within US medicine. The development of targeted agents relies on an innovative platform. The company's strategy is focused on publishing test results to attract major pharmaceutical partners.

APRE - Aprea Book Value of One Share over the range 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for Aprea Therapeutics Inc. (APRE)

- price and consensus price forecast:
Price Chart Aprea|APRE - Fair Value Consensus
- market capitalization data:
Market Capitalization Aprea Therapeutics, Inc.|APRE - Total Enterprise Value
- book capitalization data:
Book Value per Share Aprea Therapeutics|APRE - Book Value of Business|Market Capitalization to Book Value Ratio aprea.com|APRE - Company Assets
- debt and liquidity data:
Debt to Equity Aprea Therapeutics|APRE - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Aprea|APRE - Company Cumulative Debt|Debt to Book Capitalization Ratio Aprea Therapeutics, Inc.
Fundamental company valuation:APRE aprea.com
Manufactured product of Aprea Therapeutics Inc.

To identify fundamental sector leaders, the analyst evaluates the book value per share as the ratio of equity to the number of shares, which determines the theoretical value of an investor's stake upon asset liquidation. Given the R&D stage of Aprea Therapeutics (APRE), this metric reflects the volume of resources available for clinical trials, while the visualization of the book value per share allows for tracking the risk of capital impairment due to the absence of operating profit.

Competitors of Aprea Therapeutics (APRE)

Net Assets per Single Share Incyte Corp. (INCY)|HCM - Accounting Value of a Share|Book Value per Share NUVB|dayonebio.com (DAWN) - Net Asset Value per Share|Monopar Therapeutics Inc. - Book Value per Share|Book Value of One Share Inhibrx|I-Mab - Book Value per Share|Net Asset Value per Share FENC (Fennec)|HRTX - Net Assets per Single Share|Equity per Share nuvectis.com NVCT|CHRS (Coherus Biosciences) - Book Value per Share|CRBP: Net Asset Value per Share|Net Assets per Single Share cardiffoncology.com CRDF|BeyondSpring Inc (BYSI) - Accounting Value of a Share|BCAB (BioAtla Inc) - Book Value per Share|Book Value per Share LIXT|Net Assets per Single Share Citius Pharmaceuticals (CTXR)|Net Assets per Single Share Cellectar Biosciences Inc CLRB|Accounting Value per Share BioLineRx Corp|Can-Fite - Accounting Value of a Share|KZIA (Kazia) - Net Assets per Single Share|SLXN: Net Asset Value per Share|Net Assets per Single Share nucana.com|Chimerix Inc. (CMRX) - Equity per Share|Book Value per Share CYCC|Accounting Value per Share GTHX|Kronos Bio, Inc. - Net Assets per Single Share|Net Asset Value per Share KTRA (kintara.com)|Net Assets per Single Share Oncternal Therapeutics, Inc. ONCT|Portage Biotech Inc - Net Assets per Single Share